Meeting
2023 ASCO Annual Meeting
Phase I study of the mutant IDH1 inhibitor ivosidenib: Long-term safety and clinical activity in patients with conventional chondrosarcoma.
Authors
William D. Tap
Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY
William D. Tap , Gregory Michael Cote , Howard A. Burris , Lia Gore , Muralidhar Beeram , Anthony Paul Conley , Diego A. Gianolio , Zhe Qu , Camelia Gliser , Shuchi Sumant Pandya , Jonathan C. Trent
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Bone Tumors
Clinical Trial Registration Number
NCT02073994
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 11532)
DOI
10.1200/JCO.2023.41.16_suppl.11532
Abstract #
11532
Poster Bd #
466
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Breakthrough
Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.
First Author: Panpan Zhang
Poster
2024 ASCO Annual Meeting
Phase 1 trial safety and efficacy of ragistomig, a bispecific antibody targeting PD-L1 and 4-1BB, in advanced solid tumors.
First Author: Gerald Steven Falchook
Poster
2024 ASCO Gastrointestinal Cancers Symposium
The overall safety and short-term efficacy of nivolumab plus ipilimumab for advanced esophageal squamous cell carcinoma.
First Author: Kazuhiro Shiraishi
Poster
2023 ASCO Annual Meeting
Phase Ib/IIa safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced solid tumors.
First Author: Ye Guo